Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$11.48 - $17.02 $1.41 Million - $2.1 Million
123,100 Added 343.85%
158,900 $2.3 Million
Q1 2024

May 15, 2024

SELL
$15.3 - $20.24 $55,080 - $72,864
-3,600 Reduced 9.14%
35,800 $576,000
Q4 2023

Feb 14, 2024

BUY
$11.94 - $20.47 $1,194 - $2,047
100 Added 0.25%
39,400 $783,000
Q3 2023

Nov 14, 2023

SELL
$16.3 - $22.09 $96,170 - $130,331
-5,900 Reduced 13.05%
39,300 $640,000
Q2 2023

Aug 14, 2023

BUY
$19.41 - $23.43 $436,725 - $527,175
22,500 Added 99.12%
45,200 $955,000
Q1 2023

May 15, 2023

SELL
$18.06 - $25.27 $301,602 - $422,009
-16,700 Reduced 42.39%
22,700 $455,000
Q4 2022

Feb 14, 2023

BUY
$9.84 - $26.13 $387,696 - $1.03 Million
39,400 New
39,400 $1.03 Million

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.33B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.